First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial - Babiker, A; Castro nee Green, H; Compagnucci, A (Lancet Infect Dis, 2011)
et al.